Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 0Renal cell carcinoma treatmentWnt/β-catenin signaling in development and cancerCancer-related molecular mechanisms research

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index; 28 of the 36 sources its claims cite were checked for support.

PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma

Open access

Abstract

BACKGROUND: Advanced clear cell renal cell carcinoma (ccRCC) carries a dismal prognosis, urging the discovery of novel therapeutic targets. Here, we investigate the uncharacterized protein PPP1R18 as a potential driver of ccRCC malignancy. METHODS: PPP1R18 expression and its prognostic value were evaluated using TCGA, GEO, and CPTAC databases, with validation in clinical samples and cell lines. The biological functions of PPP1R18 were assessed in vitro using siRNA-mediated knockdown in a series of in vitro assays and an in vivo xenograft model. The underlying molecular mechanisms were explored through bioinformatic analysis, Western blotting, and rescue experiments using specific pathway agonists and inhibitors to delineate the signaling cascade. RESULTS: PPP1R18 is significantly upregulated in ccRCC and serves as a robust independent predictor of poor survival. Knockdown of PPP1R18 substantially impaired ccRCC cell proliferation, migration, and invasion in vitro and suppressed tumor growth in vivo. Mechanistically, PPP1R18 depletion suppressed the phosphorylation of ERK and inhibited the Wnt/β-catenin pathway, leading to a reversal of the epithelial-mesenchymal transition (EMT) phenotype. Notably, activation of the ERK pathway rescued the inhibitory effects of PPP1R18 knockdown on Wnt/β-catenin signaling and malignant phenotypes. This rescue was subsequently abrogated by a Wnt/β-catenin inhibitor, confirming that Wnt/β-catenin acts downstream of the PPP1R18/ERK axis. CONCLUSION: PPP1R18 is a crucial oncogenic driver and prognostic biomarker in ccRCC. It promotes malignant phenotypes by activating the novel ERK/Wnt/β-catenin signaling axis, offering a potential new target for ccRCC treatment.

Overview

CoChat Summary

TL;DR

PPP1R18 is upregulated in clear cell renal cell carcinoma (ccRCC), predicts poor survival, and promotes proliferation, migration, invasion, and tumor growth. Mechanistically, PPP1R18 acts through an ERK-dependent Wnt/β-catenin pathway that induces EMT.

Key findings

  • PPP1R18 was significantly upregulated in ccRCC across public datasets: TCGA-KIRC (539 tumors vs. 72 normal, P < 0.001), GSE167093 (254 pairs), GSE40435 (101 pairs), and CPTAC protein data (219 ccRCC vs. 169 normal); validation showed higher PPP1R18 protein in ccRCC cell lines and in 20 paired clinical specimens.
  • High PPP1R18 expression was associated with advanced T stage (OR = 1.54, 95% CI 1.08–2.20), distant metastasis (OR = 1.90, 95% CI 1.16–3.12), advanced pathological stage (OR = 1.56, 95% CI 1.10–2.21), and higher histological grade (OR = 2.26, 95% CI 1.35–3.77); it predicted shorter OS (HR = 1.63, 95% CI 1.20–2.20), DSS (HR = 2.42, 95% CI 1.65–3.53), and PFI (HR = 1.73, 95% CI 1.26–2.37).
  • PPP1R18 knockdown impaired ccRCC cell proliferation, migration, and invasion in vitro and suppressed tumor growth in vivo; re-expression of siRNA-resistant PPP1R18 restored these malignant phenotypes.
  • PPP1R18 depletion suppressed ERK phosphorylation and Wnt/β-catenin signaling (decreased total/nuclear β-catenin, c-Myc, Cyclin D1) and reversed EMT markers (increased E-cadherin; decreased N-cadherin and vimentin); the ERK agonist PAF(C-16) rescued these effects, while the Wnt/β-catenin inhibitor XAV-939 abrogated the rescue.

Methods

  • Bioinformatic analysis used TCGA-KIRC, GEO datasets GSE167093 and GSE40435, and UALCAN/CPTAC proteomic data; DEGs, GO/KEGG, and GSEA were analyzed in R.
  • In vitro experiments used ccRCC cell lines 786-O, Caki-1, and OSRC-2 and normal renal cell lines HEK-293 and HK-2, with siRNA-mediated PPP1R18 knockdown, siRNA-resistant PPP1R18 rescue, Western blotting, CCK-8, wound healing, and Transwell assays.
  • In vivo work used a subcutaneous xenograft model in male NDG mice (5 weeks old; n = 10, 5 per group) with 786-O cells stably expressing sh-PPP1R18 or sh-NC; tumors were measured every 3 days, excised after 3 weeks, and analyzed by IHC and Western blotting. Clinical validation included 20 paired ccRCC/adjacent tissues and 5 selected high-PPP1R18 pairs for pathway Western blots.

Limitations

  • The paper states that the tumor microenvironment is complex and that further studies, including syngeneic or pharmacological inhibition models targeting Wnt/β-catenin in vivo, are needed.
  • The paper states that the precise molecular mechanism by which PPP1R18 activates ERK remains to be fully elucidated.
  • The paper states that PPP1R18’s clinical utility as a prognostic biomarker requires validation in large-scale, prospective, multi-center cohort studies; evident from the text, the clinical pathway validation used only 5 selected paired specimens.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12935-026-04266-7

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Expression levels of PPP1R18 in ccRCC. (A) Differential mRNA expression of PPP1R18 in ccRCC (n = 539) and normal kidney tissues (n = 72) from the TCGA database. (B-D) Paired analysis of PPP1R18 mRNA levels in ccRCC and adjacent normal tissues from TCGA (n = 72 pairs) (B), GSE167093 (n = 254 pairs) (C), and GSE40435 (n = 101 pairs) (D) datasets. (E) Protein expression of PPP1R18 in ccRCC and normal kidney tissues from the CPTAC database. (F) Protein levels of PPP1R18 in ccRCC cell lines and normal kidney cell lines. (G) Representative Western blot analysis of PPP1R18 protein levels in 20 pairs of ccRCC tumors (T) and their adjacent normal tissues (N). ***p < 0.001
Fig. 1 Expression levels of PPP1R18 in ccRCC. (A) Differential mRNA expression of PPP1R18 in ccRCC (n = 539) and normal kidney tissues (n = 72) from the TCGA database. (B-D) Paired analysis of PPP1R18 mRNA levels in ccRCC and adjacent normal tissues from TCGA (n = 72 pairs) (B), GSE167093 (n = 254 pairs) (C), and GSE40435 (n = 101 pairs) (D) datasets. (E) Protein expression of PPP1R18 in ccRCC and normal kidney tissues from the CPTAC database. (F) Protein levels of PPP1R18 in ccRCC cell lines and normal kidney cell lines. (G) Representative Western blot analysis of PPP1R18 protein levels in 20 pairs of ccRCC tumors (T) and their adjacent normal tissues (N). ***p < 0.001CC BY · PubMed Central
Fig. 2 Clinical and prognostic significance of PPP1R18 expression in ccRCC. (A) Correlation of PPP1R18 mRNA expression with T stage, N stage, M stage, histological grade, and pathological stage in the TCGA cohort. (B) Correlation between PPP1R18 protein expression and histological grade in the CPTAC cohort. (C) Kaplan-Meier analysis of Overall Survival (OS), Disease-Specific Survival (DSS), and Progression-Free Interval (PFI) based on PPP1R18 mRNA expression levels. *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 2 Clinical and prognostic significance of PPP1R18 expression in ccRCC. (A) Correlation of PPP1R18 mRNA expression with T stage, N stage, M stage, histological grade, and pathological stage in the TCGA cohort. (B) Correlation between PPP1R18 protein expression and histological grade in the CPTAC cohort. (C) Kaplan-Meier analysis of Overall Survival (OS), Disease-Specific Survival (DSS), and Progression-Free Interval (PFI) based on PPP1R18 mRNA expression levels. *p < 0.05, **p < 0.01, ***p < 0.001CC BY · PubMed Central
Fig. 3 Functional assays following PPP1R18 knockdown and re-expression in ccRCC cells. (A) Western blot analysis assessing the knockdown and re-expression efficiency of PPP1R18 in 786-O and Caki-1 cells. (B) CCK-8 assay of cell viability in 786-O and Caki-1 cells transfected with si-NC or si-PPP1R18. (C) Wound healing assay in 786-O and Caki-1 cells after PPP1R18 knockdown. (D-E) Transwell migration and invasion assays in 786-O (D) and Caki-1 (E) cells after PPP1R18 knockdown. (F-H) Rescue experiments using an siRNA-resistant PPP1R18 construct (PPP1R18si−res) in PPP1R18-knockdown cells, including proliferation (F), migration (G), and invasion (H) assays. All quantitative data are presented as the mean ± SD from at least three independent experiments. Images are representative of at least three independent experiments. **p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 3 Functional assays following PPP1R18 knockdown and re-expression in ccRCC cells. (A) Western blot analysis assessing the knockdown and re-expression efficiency of PPP1R18 in 786-O and Caki-1 cells. (B) CCK-8 assay of cell viability in 786-O and Caki-1 cells transfected with si-NC or si-PPP1R18. (C) Wound healing assay in 786-O and Caki-1 cells after PPP1R18 knockdown. (D-E) Transwell migration and invasion assays in 786-O (D) and Caki-1 (E) cells after PPP1R18 knockdown. (F-H) Rescue experiments using an siRNA-resistant PPP1R18 construct (PPP1R18si−res) in PPP1R18-knockdown cells, including proliferation (F), migration (G), and invasion (H) assays. All quantitative data are presented as the mean ± SD from at least three independent experiments. Images are representative of at least three independent experiments. **p < 0.01, ***p < 0.001, ****p < 0.0001CC BY · PubMed Central
Fig. 4 Enrichment analysis and effect of PPP1R18 on Wnt/β-catenin and EMT signaling. (A) Volcano plot showing differentially expressed genes (DEGs) between the high and low PPP1R18 expression groups in the TCGA-KIRC dataset (logFC > 0.585 and p.adj < 0.05). (B) Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of the DEGs. (C) Gene Set Enrichment Analysis (GSEA) of the DEGs. (D) Western blot analysis showing decreased levels of Wnt/β-catenin pathway-related proteins after PPP1R18 knockdown in 786-O and Caki-1 cells, and the rescue of their expression by an siRNA-resistant PPP1R18 construct (PPP1R18si−res). The lower blots show β-catenin expression in five paired samples of ccRCC tumors (T) and adjacent normal tissues (N). (E) Western blot analysis of Wnt/β-catenin pathway-related proteins in 786-O and Caki-1 cells following PPP1R18 knockdown and rescue with PPP1R18si−res. The lower blots show representative expression of E-cadherin and N-cadherin in five paired samples of ccRCC tumors (T) and adjacent normal tissues (N). The Western blot results are representative of three independent experiments
Fig. 4 Enrichment analysis and effect of PPP1R18 on Wnt/β-catenin and EMT signaling. (A) Volcano plot showing differentially expressed genes (DEGs) between the high and low PPP1R18 expression groups in the TCGA-KIRC dataset (logFC > 0.585 and p.adj < 0.05). (B) Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of the DEGs. (C) Gene Set Enrichment Analysis (GSEA) of the DEGs. (D) Western blot analysis showing decreased levels of Wnt/β-catenin pathway-related proteins after PPP1R18 knockdown in 786-O and Caki-1 cells, and the rescue of their expression by an siRNA-resistant PPP1R18 construct (PPP1R18si−res). The lower blots show β-catenin expression in five paired samples of ccRCC tumors (T) and adjacent normal tissues (N). (E) Western blot analysis of Wnt/β-catenin pathway-related proteins in 786-O and Caki-1 cells following PPP1R18 knockdown and rescue with PPP1R18si−res. The lower blots show representative expression of E-cadherin and N-cadherin in five paired samples of ccRCC tumors (T) and adjacent normal tissues (N). The Western blot results are representative of three independent experimentsCC BY · PubMed Central
Fig. 5 Regulation of Wnt/β-catenin signaling via the ERK pathway. (A) Western blot analysis of phospho-ERK (p-ERK) and total ERK in 786-O and Caki-1 cells under the indicated conditions (PPP1R18 knockdown, PPP1R18si−res rescue, and ERK agonist PAF(C-16) treatment). The lower blots show representative expression of p-ERK and total ERK in 5 pairs of ccRCC tumors (T) and adjacent normal tissues (N). (B) Western blot analysis of Wnt/β-catenin pathway proteins in cells treated with si-PPP1R18 and PAF(C-16). The results are representative of three independent experiments
Fig. 5 Regulation of Wnt/β-catenin signaling via the ERK pathway. (A) Western blot analysis of phospho-ERK (p-ERK) and total ERK in 786-O and Caki-1 cells under the indicated conditions (PPP1R18 knockdown, PPP1R18si−res rescue, and ERK agonist PAF(C-16) treatment). The lower blots show representative expression of p-ERK and total ERK in 5 pairs of ccRCC tumors (T) and adjacent normal tissues (N). (B) Western blot analysis of Wnt/β-catenin pathway proteins in cells treated with si-PPP1R18 and PAF(C-16). The results are representative of three independent experimentsCC BY · PubMed Central
Fig. 6 Role of the ERK/Wnt/β-catenin axis in PPP1R18-mediated progression. (A-C) Analysis of cell proliferation (A), migration (B), and invasion (C) in PPP1R18-knockdown cells treated with the ERK agonist PAF(C-16) and/or the Wnt/β-catenin inhibitor XAV-939. (D) Western blot analysis of Wnt/β-catenin pathway proteins and EMT markers in PPP1R18-knockdown cells treated with PAF(C-16) with or without XAV-939. All quantitative data are presented as the mean ± SD from at least three independent experiments. Images are representative of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 6 Role of the ERK/Wnt/β-catenin axis in PPP1R18-mediated progression. (A-C) Analysis of cell proliferation (A), migration (B), and invasion (C) in PPP1R18-knockdown cells treated with the ERK agonist PAF(C-16) and/or the Wnt/β-catenin inhibitor XAV-939. (D) Western blot analysis of Wnt/β-catenin pathway proteins and EMT markers in PPP1R18-knockdown cells treated with PAF(C-16) with or without XAV-939. All quantitative data are presented as the mean ± SD from at least three independent experiments. Images are representative of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001CC BY · PubMed Central
Fig. 7 Effect of PPP1R18 knockdown on ccRCC tumor growth in vivo. (A) Representative images of tumors from the sh-NC and sh-PPP1R18 groups (n = 5 per group). (B) Tumor growth curves for the sh-NC and sh-PPP1R18 groups. Tumor volumes were measured every 3 days. (C) Final tumor weights at the end of the experiment. (D) Representative immunohistochemistry (IHC) staining images for PPP1R18 and Ki-67 in xenograft tumor tissues from both groups. (E) Western blot analysis of β-catenin, p-ERK, N-cadherin, and E-cadherin protein levels in xenograft tumor tissues. Data are presented as the mean ± SD (n = 5 mice per group). Western blot images are representative of tumor samples from the respective groups. **p < 0.01, ****p < 0.0001
Fig. 7 Effect of PPP1R18 knockdown on ccRCC tumor growth in vivo. (A) Representative images of tumors from the sh-NC and sh-PPP1R18 groups (n = 5 per group). (B) Tumor growth curves for the sh-NC and sh-PPP1R18 groups. Tumor volumes were measured every 3 days. (C) Final tumor weights at the end of the experiment. (D) Representative immunohistochemistry (IHC) staining images for PPP1R18 and Ki-67 in xenograft tumor tissues from both groups. (E) Western blot analysis of β-catenin, p-ERK, N-cadherin, and E-cadherin protein levels in xenograft tumor tissues. Data are presented as the mean ± SD (n = 5 mice per group). Western blot images are representative of tumor samples from the respective groups. **p < 0.01, ****p < 0.0001CC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 0 Not valid · 1 Not checked · 92 Own results and interpretations

66 more claims

Create a free account to see all 103 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 21
  • Probably not a substantial claim. 14
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 64 references

Metadata

Authors
Ji, X., Yun, Y., Zhu, Z., Wu, T., Ruan, M., Fan, Y., & Zhang, Q.
Affiliations
  • Capital Medical University (CN)
  • Peking University (CN)
Corresponding author
  • Fan, Yu
  • Zhang, Qian
Venue
Cancer Cell International
Published
2026-05-10
Volume
26
Issue
1
ISSN
1475-2867 (ISSN-L)
OpenAlex
W7160765552
Cited by
0
References
64
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer Cell International (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Natural Science Foundation of China (82072826)
Topics
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
clear cell renal cell carcinoma, Wnt/β-catenin signaling, ERK signaling, epithelial-mesenchymal transition, prognostic factors, oncogenic drivers, tumor cell proliferation, migration and invasion, therapeutic target

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma. https://app.cochat.ai/papers/10.1186/s12935-026-04266-7
The paper
Ji, X., Yun, Y., Zhu, Z., Wu, T., Ruan, M., Fan, Y., & Zhang, Q. (2026). PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma. Cancer Cell International. https://doi.org/10.1186/s12935-026-04266-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.